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Review Article
Ablation of long-standing persistent atrial fibrillation
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Abstract: Atrial fibrillation (AF) is the most commonly encountered arrhythmia in the clinical setting 
affecting nearly 6 million people in United States and the numbers are only expected to rise as the population 
continues to age. Broadly it is classified into paroxysmal, persistent and longstanding persistent AF. 
Electrical, structural and autonomic remodeling are some of the diverse pathophysiological mechanisms that 
contribute to the persistence of AF. Our review article emphasizes particularly on long standing persistent 
atrial fibrillation (LSPAF) aspect of the disease which poses a great challenge for electrophysiologists. While 
pulmonary vein isolation (PVI) has been established as a successful ablation strategy for paroxysmal AF, 
same cannot be said for LSPAF owing to its long duration, complexity of mechanisms, multiple triggers and 
substrate sites that are responsible for its perpetuation. The article explains different approaches currently 
being adopted to achieve freedom from atrial arrhythmias. These mainly include ablation techniques chiefly 
targeting complex fractionated atrial electrograms (CFAE), rotors, linear lesions, scars and even considering 
hybrid approaches in a few cases while exploring the role of delayed enhancement magnetic resonance 
imaging (deMRI) in the pre-procedural planning to improve the overall short and long term outcomes of 
catheter ablation. 
Keywords: Long standing persistent atrial fibrillation (LSPAF); catheter ablation; hybrid ablation; complex 
fractionated atrial electrograms (CFAE); linear lesion; rotors; pulmonary vein isolations (PVI)
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Introduction
Atrial fibrillation (AF), the most commonly encountered 
arrhythmia, is defined as a disorganization in the electrical 
impulses of the upper chambers of the heart resulting in 
an irregular heartbeat leading to an interrupted blood 
flow from atria to the ventricles (1). Currently AF affects 
a population of 2.7 to 6.1 million adults in United States. 
Almost 2% and 9% of adults below and above the age 
of 65, respectively have AF (2). The annual cost of AF is 
estimated to be $6 billion (3,4). The economic impact of 
this debilitating condition continues to increase with the 
aging population and the ever increasing comorbidities 
such as hypertension, diabetes mellitus, heart failure, 
chronic kidney disease, ischemic heart disease, obesity and 
hyperthyroidism (4). 
Classification
For standardization, AF is further categorized into 
paroxysmal, persistent or longstanding persistent according 
to the guidelines stated by American College of Cardiology, 
European Society of Cardiology and American Heart 
Association (5). Paroxysmal AF occurs when a patient has 
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at least two recurrent episodes that self-terminate within 
7 days. An AF episode is defined as one that is documented 
by electrocardiogram (ECG) monitoring and has a duration 
of at least 30 seconds, or if less than 30 seconds, is present 
continuously throughout the ECG monitoring tracing. 
Paroxysmal AF also includes the patient population in 
which cardioversion is performed within 48 hours of onset. 
Persistent AF occurs when the arrhythmic episodes endure 
beyond 7 days or require cessation with pharmacological 
or direct current cardioversion between 48 hours to 7 days 
duration. Continuous incidences of AF extending greater 
than 12 months are classified as longstanding persistent 
(5-7). Silent AF is characterized as an incidental finding on 
ECG or rhythm strip in an asymptomatic patient. Once 
identified, it can then be additionally characterized into any 
of the above listed categories (5). Furthermore, patients 
being considered as a candidate for catheter/surgical 
ablation for AF should be reclassified and not listed as 
permanent AF. This term remains exclusive for patients in 
which it is determined not to restore sinus rhythm by any 
technique (5). 
Goal of review
Successful ablation of long-standing persistent atrial 
fibrillation (LSPAF) has been a challenging task for many 
electrophysiologists. As per current joint American Heart 
Association, American College of Cardiology and Heart 
Rhythm Society guidelines, catheter ablation may be 
considered for symptomatic LSPAF prior to initiation, or if 
refractory/intolerant to, at least one class I or class III anti-
arrhythmic medication (class IIb indication) (3). The goal 
of this review is to discuss the mechanisms that maintain 
LSPAF, the various catheter ablation strategies that are 
currently being utilized, and their success with short- and 
long-term freedom from recurrent atrial arrhythmias. Many 
of the studies that will be discussed assess various substrate 
modification and trigger ablation strategies in patients 
with various stages of AF however most studies combine 
the analyses of success in patients with persistent AF and 
LSPAF. Given this limitation, we will focus on LSPAF. 
Mechanism
Early in the clinical process, the pulmonary veins (PV) (5,8) 
remain the main site of ectopic foci that initiate AF which 
explains a success rate as high as 85% with pulmonary 
vein isolation (PVI) catheter ablation (6) (Figure 1). As 
AF evolves from paroxysmal to persistent, as a result of 
complex underlying electro-structural modifications, the 
success rate begins to decrease (5). In 1959, Moe et al. 
presented one of the prevailing theories explaining the 
concept of AF: the multiple wavelet hypothesis (9). AF 
propagates through existing wavelets which in turn are 
dependent on diminished conduction, reduced refractory 
periods and an enlarged atrial mass. The localized source 
hypothesis cultivates the idea of rotors or focal impulses as 
the leading etiology of disorganized AF (10,11). In 1994, 
Haïssaguerre and colleagues laid down the foundation of 
focal mechanisms of AF mainly located in the PV (12). 
Later, Ho et al. (13) also identified the cardiac tissue sleeves 
in the PV as a possible origin of ectopic foci by shedding 
some light on the long forgotten anatomical structures 
initially demonstrated by Nathan and Eliakim in 1966 (14). 
The main pathophysiological mechanisms giving rise to AF 
are electrical and structural alterations in atrial tissue as well 
as effects on of the autonomic nervous system (7).
Electrical remodeling 
Various medical conditions such as atrial tachyarrhythmias 
and heart failure make the atria susceptible to AF. 
Normal resting potential is maintained by the large 
number of potassium channels (IK1) in atrial cells. The 
key mechanisms causing focal atrial arrhythmias are 
enhanced automaticity, early afterdepolarization (EAD) 
Figure 1 PVI. A modified posterior view of a left atrial shell 
created in a 3D mapping system shows circular radiofrequency 
lesions (pink, red and green spheres) around ipsilateral pulmonary 
vein pairs. The right pulmonary veins are on the right side of the 
image and displayed en face, while the left pulmonary veins are 
on the left of the image displayed laterally. PVI, pulmonary vein 
isolation.
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and delayed afterdepolarizations (DAD) (7). Automaticity, 
or spontaneous depolarization, does not occur in normal 
atrial myocardial cells (15). Enhanced automaticity occurs 
when there is an imbalance of potassium channels (IK1) and 
pacemaker current (If) or when there is decreased capacity 
of IK1 channel to transport potassium ions (7,15). Excessive 
prolongation of action potential duration causes the 
development of EAD. It involves early activation of calcium 
channel [L-type Ca (I CaL)] during the repolarization phase 
allowing inward entry of calcium ions (7,16). Conditions 
predisposing to EAD include injured myocardial tissue, 
heart failure, electrolytic disturbances, hypoxia, acidosis and 
antiarrhythmic agents (15). DADs occur when there is an 
abnormal diastolic outflow of calcium from sarcoplasmic 
reticulum calcium stores as a response to transmembrane 
calcium entry. An excess of diastolic calcium ensues an 
exchange of a single calcium ion for three extracellular 
sodium ions creating a net positive environment by 
transient inward current (Iti) that creates DADs (7,16). 
Repetitive DADs lead to focal atrial tachycardias (16). 
DADs are usually seen during digitalis toxicity and elevated 
catecholaminergic levels (15). Hence electric remodeling 
due to underlying atrial conditions can contribute to 
progression of AF from a paroxysmal to a persistent form.
Autonomic remodeling
Autonomic remodel ing or  interplay between the 
sympathetic and parasympathetic systems can also generate 
ectopic foci within the left atrium (LA) to create and 
propagate AF (17). Both animal and human models alike 
have shown an association between AF and abnormal 
autonomic system function. Numerous autonomic ganglia 
are located in the LA with the highest concentration within 
5 mm of PV-LA junction. Approximately 30% of ganglionic 
cells have both adrenergic and cholinergic properties (18). 
Vagal discharge by parasympathetic system and sympathetic 
activation leading to a heterogeneous increase in 
transmembranous and intracellular calcium and ultimately 
the release of norepinephrine, which can trigger focal areas 
in the LA and differentially decrease the atrial effective 
refractory period across the posterior LA, contribute to the 
initiation and preservation of AF (17). 
Ablation of the ganglionated plexi overlying the LA 
has shown some promise in patients with paroxysmal AF. 
Pappone et al. performed circumferential PV ablation in 297 
patients with paroxysmal AF; 34.3% of patients underwent 
additional vagal denervation (19). At 1 year follow up, 
patients who received additional vagal denervation were 
found to have less recurrence of AF compared to their 
counterparts. Katritsis et al. randomized 242 patients in 
his prospective study to PVI alone, ganglion plexus (GP) 
ablation alone or combined PVI-GP ablation (20). At 
2 years follow up, freedom from atrial arrhythmia was 
74%, 56%, 48% (P=0.004) in the PVI-GP, PVI-alone, and 
GP-alone cohort, respectively. Conversely, outcomes with 
PVI-GP ablation seem to not be as favorable in patients 
with persistent or LSPAF. In 2013, Zheng et al., revealed 
at approximately 5 years follow up, the success rate for 
surgical PVI-GP ablation was 51.8% for paroxysmal AF, 
28.2% for persistent AF, and 28.6% for LSPAF (21). Thus, 
the influence of the autonomic nervous system on LSPAF 
remains uncertain. 
Structure remodeling
There is growing consensus that fibrosis in the atria ranging 
from mild to severe can lead to significant advancement in 
the disease process of AF. Enhanced expression of collagen I 
in the LA can lead to excessive accumulation of collagenous 
material in the extracellular space, especially in those with 
lone AF (22). Platonov et al. studied the post-mortem atrial 
tissue samples obtained from posterior left atrial wall, at the 
level of the superior PV, inferior PV, Bachmann’s bundle 
and crista terminalis (23). Interestingly, three to five times 
greater fibrosis and fatty infiltration was noted compared to 
patients with no history of AF, regardless of tissue sampling 
site. Furthermore, the extent of fibrosis was higher in the 
permanent versus paroxysmal AF cohort. These findings 
were similar to Kuppahally et al. who demonstrated 
significantly more fibrosis in patients with persistent AF 
compared to patients with paroxysmal AF (22%±17% vs. 
14%±9%, P=0.04) (24). 
Stiles et al. in his small study of 25 patients successfully 
demonstrated the role of structural remodeling in AF (25). 
Patients with paroxysmal AF had reduced conduction 
velocity, longer effective refractory periods and much 
lower voltages as a result of abnormal atrial substrate 
which promoted progression of AF. Similar conclusions 
were also drawn by Teh et al. when they described an 
electroanatomic substrate in the LA beyond the focus of the 
PV in AF patients without any evidence of structural heart 
disease (26). In fact, patients with persistent AF were more 
likely to have a greater proportion of low voltage, slower 
conduction and increased area of complex signals compared 
to paroxysmal AF group. Structural atrial remodeling has 
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also been observed at a cellular level in animal models 
as a result of rennin-angiotensin system activation (6). A 
study in transgenic rats demonstrated that stretching of 
the atrial musculature leads to release of angiotensin II and 
transforming growth factor-B1which in turn stimulates 
interstitial fibrosis and dilatation of atria (27). It remains 
unclear if atrial fibrosis is a cause or consequence of AF. 
Evidence from numerous studies now helps us 
understand some of the fundamental points of structural 
remodeling. First, fibrosis helps AF persist and thus 
facilitates the transformation from paroxysmal to persistent. 
Second, as AF transitions from paroxysmal to persistent, the 
location of the substrate for AF gradually shifts away from 
the PV which may ultimately guide the ablation approach 
for each individual patient. 
Typically, patients with hypertension are thought to be 
more vulnerable to development of AF given its association 
with atrial fibrosis. Uncontrolled systemic hypertension 
can lead to LA remodeling due to increased pressure and 
volume overload. Not surprisingly, the relationship between 
average systolic blood pressure and AF is stronger for 
persistent AF compared to paroxysmal AF (28). The atrial 
remodeling that is associated with systemic hypertension 
has been also characterized by global conduction 
slowing, regional conductional delays and increased AF 
inducibility (29). Mahnkopf et al. compared LA structural 
changes in lone AF patients to the patients with common 
conditions like hypertension, diabetes mellitus, congestive 
heart failure, stroke and coronary artery disease through 
delayed enhancement magnetic resonant imaging (DE-
MRI) (30). They found that the extent of LA remodeling 
was totally independent of the most common comorbidities 
and the type of AF. Oakes et al. had a similar observation 
in their study of 81 patients demonstrating a high degree 
of variability in LA structural remodeling regardless of the 
category of AF (31).
Complex fractionated electrograms
Complex fractionated electrograms (CFAE) was first 
described in 2004 by Nademanee et al. (32). While there 
is much debate as to what qualifies as CFAE, many 
investigators define them as continuous atrial activity, 
complex fractionated potentials or low voltage electrograms 
with a short cycle length of less than 120 milliseconds 
over a 10-second period (32-34) (Figure 2). Gerstenfeld 
studied the mechanism of CFAE in canine models. He 
described wavefront collision as the most common form of 
activation in the region of CFAE (48%) whereas abnormal 
conduction through areas of functional block and reentry 
phenomenon were responsible for the remainder of CFAE. 
The majority of the multiple wavelets were found to be 
circulating between posterior LA and entry/exit region of 
PV (35). Konings et al. demonstrated that CFAE originate 
along the regions of slow conduction, functional block, and 
pivot points (33). All three factors facilitate the creation 
and persistence of AF. Areas of slow conduction reduce the 
wavelength of wavelets and increase their number in atria 
while the lines of conduction block disintegrate the wavelets 
and the pivot points ensure timely rotation of the wavelets 
to prevent their termination at the atrial boundaries. These 
abnormal conduction patterns in the atria, if identified, can 
serve as a potential target for ablation.
Role of rotors
Rotors are defined as regions of functional reentry 
responsible for driving AF (36). Davidenko et al. first 
demonstrated the self-sustaining rotating waves, introduced 
by delivering a single premature electrical stimulus in a 
normal epicardial myocardium (11). Once instigated, this 
gives rise to an infinite circulation of self-propagating 
waves which can be dissipated only by providing a precisely 
timed electrical stimulus. Decades of similar studies have 
proven that rotors are a primary phenomenon rather 
than a secondary event disseminating spiral waves into 
the surrounding the tissue (37). Rotors are enabled by 
the ionic and conduction defects at the cellular level and 
intermittent areas of fibrosis lead to stabilization of rotors 
(36,37). Techniques such as optical mapping, epicardial 
contact electrodes with high spatiotemporal resolution 
assist in revealing the location of rotors hence making them 
potentially amenable for ablation (38,39). However, the 
importance of rotors to human AF remains controversial. 
More recently, high resolution mapping has shown some 
evidence that dissociated fibrillation waves originating 
from different directions on the endo-epicardial surface 
may act as the main substrate of LSPAF (40). Nevertheless, 
additional investigations into underlying mechanism of 
propagation of LSPAF are crucial to the development of 
successful ablation strategies.
Ablation strategies
PVI has been shown to be a very effective ablation 
technique in patients with paroxysmal AF but may not be 
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as effective by itself in patients with persistent or LSPAF 
(41,42). The reason for contrasting success rates is likely 
due to the different mechanisms, additional triggers and 
substrate that maintain persistent AF. We will now discuss 
the adjunctive catheter ablation techniques including 
linear lesions, modulation of rotors and focal impulses, 
CFAEs, substrate modification including assessing atrial 
fibrosis, isolation of left atrial appendage, and surgical based 
approach.
Linear lesions
Linear ablation has been utilized to create electrical barriers 
that prevent single macro-reentrant wavefronts from 
circulating. Swartz et al. initially performed RF ablation 
with multiple long linear ablation lines in both atria 
deemed as an endocardial replica of the MAZE procedure 
(43,44). In 1999, Ernst et al. investigated the safety and 
efficacy of biatrial linear ablation versus right atrium (RA) 
ablation only which included an isthmus line between the 
inferior vena cava (IVC) and tricuspid annulus, an anterior 
line between the superior vena cava (SVC) and tricuspid 
annulus, and an intercaval line between the ostia of the 
IVC and SVC in patients with idiopathic AF (45). Due to 
difficulty in creating a left atrial lesion set connecting the 
PV ostia with mitral annulus (MA), 100% recurrence was 
noted in the biatrial arm and 94% recurrence in the RA 
ablation arm despite a complete linear lesion set in 56% of 
patients, concluding that successful linear ablation in the 
RA does not prevent AF recurrence. In 2003, Ernst et al. 
investigated the efficacy of linear lesions within the LA in 
patients with intermittent or chronic symptomatic AF (mean 
duration 10±8 years), assessing various strategies including 
(I) circular lesion around all PV ostia and a connection to 
MA; (II) three linear lesions, including a roof line from 
right superior to left superior (LS) PV, ablation from mid-
roof line to anterior MA, and from roof line to posterior 
MA; (III) separate encircling lesions around the right and 
left PV with linear lesions along the posterior LA wall and 
towards the lateral MA; and (IV) encircling lesions as in set 
C but without the linear lesions (46). Despite the inability 
to achieve conduction block across linear lesions in many 
patients, 74% of patients were found to have freedom from 
AF at long-term follow up (620±376 days). Not only did 
this study reinforce the difficulties in creating long linear 
lesions and its propensity for LA macroreentry due to 
conduction gaps, but that durable PVI at a minimum is vital 
in successful termination of AF. 
Jaïs et al. evaluated PVI and cavotricuspid isthmus 
(CTI) linear ablation in 100 patients with drug refractory 
Figure 2 CFAE. Recording of CFAE on a circular mapping catheter (PV 1–2 through 9–10) in the left atrium. Note the high frequency, 
rapid activation in PV 1–2, 2–3, 4–5, 5–6, 8–9, 9–10 compared to PV 3–4 and 7–8, as well as coronary sinus (Sd and 3–4). An ablation 
catheter (BL) shows CFAE on the proximal (p) pole, but not the distal (d). Also shown are surface ECG leads I and II. CFAE, complex 
fractionated atrial electrograms.
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symptomatic AF and examined its efficacy compared to 
100 patients undergoing the same procedure plus linear 
mitral isthmus (MI) ablation [lateral MA to left inferior (LI) 
PV] (47) (Figure 3). At 1 year follow up, this prospective 
non-randomized study revealed 87 patients with MI 
ablation in sinus rhythm compared to 69 patients without 
(RR for AF recurrence 0.2; 95% CI 0.1–0.4; P<0.001). In 
their prospective randomized study including 187 patients, 
Fassini et al. also were able to demonstrate that the addition 
of MI line compared to PVI alone was more successful in 
maintaining sinus rhythm at 1 year follow up (71%±5% 
vs. 53%±5%, P<0.01) especially in patients with persistent 
AF (48). Feasibility of roofline ablation, linear block 
between the right and LS PVs, was initially studied by 
Hocini and colleagues in 2005 (49). Ninety patients with 
drug refractory paroxysmal AF were divided into two 
cohorts: empiric LA roof linear ablation plus PVI and PVI 
alone. At 15±4 months follow up, significantly more patients 
in the roofline group were arrhythmia-free compared to 
those with PVI alone (87% vs. 69%, P=0.04). Roofline 
ablation also resulted in an increase in the fibrillatory 
cycle length, termination, and subsequent noninducibility 
of AF. Wu et al. investigated whether a pure extensive 
linear ablation including roofline, MA and CTI without 
PVI was associated with better long term outcome in 120 
consecutive patients with drug refractory persistent AF (50). 
Despite initial successful ablation and conversion to sinus 
rhythm in 62.5%, a median follow up period of 5.1 years 
demonstrated that sinus rhythm was maintained without 
antiarrhythmic drugs in only 40% of patients. 
CFAE
In 2004, Nademanee et al. suggested ablation of AF through 
a CFAE-based approach (32). Out of 121 patients enrolled, 
76% achieved freedom from AF at 1 year follow up after 
one procedure, and 91% after up to two procedures. 
Although standard PVI was not performed, most of the 
CFAE targeted for ablation originated in PV. While these 
initial results were promising, many other investigators 
were unable to achieve the same success. 
Oral et al. performed CFAE ablation in the LA and 
coronary sinus in 100 patients with persistent AF; freedom 
from AF was only 33% at 14±7 months follow up (51). 
In 2009, Oral et al. then randomized 100 patients with 
LSPAF who had failed antral PVI to either have additional 
CFAE ablation or cardioversion (50 in each group) (52). At 
10±3 months follow up, 36% vs. 34% (P=0.84) were in 
sinus rhythm in the cardioversion and CFAE groups, 
respectively. The Substrate and Trigger Ablation for 
Reduction of Atrial Fibrillation Trial (STAR-AF), a 
randomized control multicenter international study in 
2010, performed head-to-head comparison of CFAE vs. 
PVI vs. PVI plus CFAE in 100 patients with either high 
burden paroxysmal AF or persistent AF (53). At 1 year 
follow up, 74% of patients in CFAE plus PVI group 
remained in sinus rhythm after their first procedure 
which increased to 88% after two procedures. In contrast, 
successful ablation was reported in only 29% in the CFAE-
only cohort which improved to 38% after two procedures. 
A meta-analysis comprising of 8 studies and 760 patients 
revealed a statistically significant freedom from AF in 
CFAE and PVI cohort in persistent AF patients compared 
to paroxysmal AF (54). However, in 2015, Providência 
et al. performed a meta-analysis of 13 studies involving 
1,415 patients and revealed PVI plus CFAE revealed no 
superiority over the standard PVI procedure in patients 
with paroxysmal or persistent AF patients (55). Estner 
et al. also compared CFAE technique to linear ablation in 
addition to standard PVI in 116 patients with persistent 
AF (56) .  Both CFAE and l inear ablat ion cohorts 
yielded similar results in terms of freedom from atrial 
tachyarrhythmias at 1 year follow up (56% vs. 54%, P=0.8). 
Nonetheless a greater recurrence of AF was detected in PVI 
plus linear ablation group compared to patients assigned to 
Figure 3 MI Line. A left lateral view of the left atrial shell (grey) 
on a 3D mapping system shows ablation lesions (red hexagons) 
encircling the LS and LI PV. An additional linear lesion set is seen 
connecting the inferior MA to the LIPV lesion set. Also seen is the 
LAA. MI, mitral isthmus; LS, left superior; LI, left inferior; PV, 
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PVI and CFAE ablation in whom atrial tachycardia was more 
commonly seen. 
CFAE ablation beyond PVI does not necessarily enhance 
single procedure efficacy in ablating persistent or LSPAF. 
The RASTA study demonstrated that the addition of 
LA CFAE ablation with PVI was less efficacious to both 
PVI plus ablation of non-PV triggers using a stimulation 
protocol (standard approach) as well the standard approach 
plus empirical ablation of common non-PV AF trigger 
sites (MA, fossa ovalis, eustachian ridge, crista terminalis, 
and SVC) (57). Interestingly, patients who underwent 
repeat ablation for arrhythmia recurrence had at least 
1 PV reconnection (≥3 PVs in most subjects). Targeting 
these sites alone resulted in excellent long term (80%) 
AF control rates suggesting that durable PVI should be 
the cornerstone when addressing ablation in persistent 
or LSPAF. The STAR-AF II trial compared the approach 
of PVI plus CFAE ablation vs. other standard ablation 
strategies [PVI plus linear lesions (LA + MI) vs. PVI 
alone] in a randomized fashion with patients in persistent 
AF (41). The trial concluded that there was no statistically 
significant reduction in the rate of recurrent AF with the 
addition of linear or CFAE ablation to PVI alone after the 
initial blanking period and at 18 months follow up. The 
addition of CFAE and linear ablation resulted in longer 
procedure time, increased fluoroscopy exposure and slightly 
worse procedural adverse effects. Recently, Kim et al. 
investigated the combination strategy of combining PVI 
and linear lesions followed by CFAE ablation in patients 
with LSPAF (58). Interestingly, his prospective randomized 
study revealed that additional CFAE ablation resulted in 
a numerically (but statistically insignificant) higher AF 
recurrence compared to PVI + linear lesions (32.1% vs. 
18.5%, P=0.166).
The basis for conflicting data on the CFAE lies in the 
fact that CFAE can be a nonspecific indicator of key target 
sites (34). All CFAEs are not equivalent, and they can be 
created by passive mechanisms that do not play an active 
part in propagation of AF (34,59). Further investigation into 
distinguishing passive versus active CFAE sites may lead to 
more promising outcomes. 
Focal impulse and rotor modulation (FIRM)
As mentioned above, rotors and focal impulses have been 
suggested by some investigators to be localized sources 
that sustain paroxysmal, persistent and LSPAF. FIRM had 
initially shown promise to improve the outcome of AF 
ablation in paroxysmal and persistent AF patients with 
the intention of eradication of local sources and rotors on 
repeat FIRM mapping (60). The Conventional Ablation 
for Atrial Fibrillation with or without Focal Impulse and 
Rotor Modulation (CONFIRM) trial, a non-randomized 
prospective study, revealed that bi-atrial FIRM guided 
ablation prior to conventional (PVI) ablation resulted in 
an 85% success rate with acute termination of a mixed 
population AF vs.  20% with conventional ablation 
alone (61). Narayan et al. later published the long term 
efficacy of FIRM guided ablation in the 3 years follow up 
of the CONFIRM trial: freedom from AF after 890 days 
was 77.8% vs. 38.5% in those who received FIRM-guided 
plus conventional ablation and conventional PVI alone, 
respectively (62). 
In 2014, Miller et al. performed a prospective registry 
study of mixed AF patients (9% LSPAF) who underwent 
FIRM-guided ablation followed by conventional PVI 
ablation at 10 experienced ablation centers (63). AF sources 
were detected in 100% of patients with each having an 
average of 2.3±0.9 rotors or focal sources. Interestingly, 
patients with persistent AF had a higher number of atrial 
AF sources compared to those with paroxysmal AF, 
reinforcing the idea that rotor and focal impulses play 
a large role in sustaining non-paroxysmal AF. At 1 year 
follow up, freedom from AF as a result of single procedure 
was observed in 80.5% (62/77) of patients and 87.5% 
of patients who had no prior ablation procedure (35/40; 
n=32 persistent/longstanding persistent). However, these 
outcomes were not statistically significant (18/23, 78.3% 
vs. 44/54, 81.5%, P=0.89) between patients who suffered 
from paroxysmal versus persistent AF, respectively. Spitzer 
et al. published successful long term outcomes with FIRM 
guided combined with conventional ablation (PVI) in 
patients with non-paroxysmal AF (83% LSPAF) who had 
failed prior conventional ablation (64). At 6 and 12 months 
follow-up, 73.2% and 76.9% of patients were free from AF/
AT, respectively. Miller et al. recently reported favorable 
long term outcomes noted in their registry of patients who 
had undergone FIRM-guided ablation (65). This non-
randomized single center study involved 170 patients with 
paroxysmal and non-paroxysmal AF (32% LSPAF) who 
underwent FIRM guided ablation followed by PVI (95% 
of patients). With regards to patients with LSPAF, the 
combination of FIRM-guided and conventional ablation 
resulted in acute termination of AF in 19% of patients. At 
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1 year follow up, 82% of patients with LSPAF had freedom 
from AF without AAD after a single procedure and 57% 
with freedom from all atrial arrhythmias. 
Despite the promising results of the above mentioned 
non-randomized studies of FIRM ablation, they have 
not been validated by independent investigators or with 
randomized clinical trials. In 2016, the observational 
study published by Buch et al. revealed poor long-term 
outcomes with FIRM-guided ablation in patients with 
paroxysmal and persistent AF; only 37% of patients were 
free from AF at 18±7 months follow up (66). Steinberg 
et al. also demonstrated low long-term efficacy with FIRM-
guided ablation in various AF classes in their single-center 
observational study (67). FIRM ablation was performed in 
43 patients (72% with median of one prior PVI), followed 
by redo PVI in 31/43 patients. At 16±10.7 months follow 
up, nine (21%) were free from AF. One could argue the 
success of the FIRM-guided ablation studies with favorable 
outcomes are attributed to adjunctive PVI. As mentioned 
multiple times in this review, PVI remains the foundation 
to all AF catheter ablations. Given these studies are non-
randomized with no PVI control group, it is difficult 
to conclude that FIRM guided ablation is the answer. 
Furthermore, the signal processing algorithms used for 
FIRM mapping by the only system commercially available 
(Topera Solution, Abbott, Menlo Park, CA) has not been 
fully revealed its manufacturer. Additionally, the 64-pole 
basket catheter generally covers about 50% of the atrial 
surface area, calling into question the ability of the system 
to identify rotors on the order of a few cm2. As a stand-
alone ablation methodology for non-paroxysmal AF, 
FIRM guided ablation alone has not been shown to be 
efficacious (68). 
Substrate ablation
Recently considerable work has been done to explore atrial 
scar sites as a possible arrhythmic substrate responsible 
for preservation of AF. As mentioned earlier, AF induces 
electrophysiologic and cellular changes which result in its 
persistence (“AF begets AF”) (8,69). Delayed enhancement 
magnetic resonance imaging (deMRI) has been used to 
assess LA fibrosis prior to ablation, and quantify ablation 
induced scarring. A single center study revealed that the 
degree of circumferential PV scar has been inversely 
correlated to procedure success (70). The feasibility of 
quantifying atrial fibrosis prior to AF using deMRI was 
investigated in the deMRI-guided Fibrosis Ablation vs. 
Conventional Catheter Ablation of Atrial fibrillation 
(DECAAF), a multicenter, prospective observational cohort 
study. Arrhythmia recurrence was associated with the degree 
of left atrial wall fibrosis: for every 1% increase in fibrosis, 
HR was 1.06 (95% CI 1.03–1.08; P<0.001) (71).
Catheter ablation based on individual scar distribution 
is the emerging approach for treatment of persistent AF. In 
2005, Verma and colleagues identified patients with areas 
of scar in LA and showed that these patients had higher 
incidence of AF recurrence (57%) when compared to 
patients with no left atrial scar (19%). Additionally, these 
patients had larger LA size, lower ejection fraction, greater 
levels of inflammatory markers, and lower success rates with 
catheter ablation. 
Rolf et al. correlated low voltage areas in LA (<0.5 mV) 
to LA scarring and found a higher scar burden amongst 
patients with persistent AF (35%) compared to the patients 
with paroxysmal AF (10%) (72). They reported a 70% 
success rate of ablation with targeting of LA substrate with 
low voltage areas in addition to PVI, in comparison to only 
26% in patients where PVI was the sole target. 
In a recent single center retrospective study, voltage-
guided ablation therapy was employed to the posterior 
wall of LA in addition to PVI versus PVI alone; 80% of 
the patients in PVI plus LA posterior wall group were 
free from AF in contrast to 57% of the patients with PVI 
alone (73). Yamaguchi et al. revealed that low voltage 
based substrate modification in addition to PVI is more 
efficacious in patients with persistent AF with low voltage 
zones (74). Yang and colleagues targeted PV and CTI for 
ablation in 86 patients with nonparoxysmal AF; 70% of the 
patient population were recognized to have low voltage 
areas and hence received additional ablation (75). After 30 
months follow up period, 69.8% of the patients were able 
to maintain sinus rhythm compared to 51.3% in whom no 
further procedures were performed. Studies suggest higher 
LA scar burden enable persistence of AF and targeting of 
these areas may hold promise of freedom from AF (76). 
Another novel ablation strategy called box isolation 
of fibrotic areas (BIFA) utilizes electroanatomic voltage 
mapping (EAVM) to identify fibrotic LA substrate. This 
new concept was initially tested successfully by Kottkamp 
et al. in patients with paroxysmal AF who required redo 
procedures despite durable PVI. After performing standard 
PVI and spontaneous or electrical cardioversion, low 
voltage areas were mapped, isolated and ablation lines 
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were connected to initial PVI lines. Next, he applied 
BIFA plus PVI to patients with non-paroxysmal AF who 
had low voltage areas detected by EAVM and achieved a 
successful rate of 72.2% single procedure freedom from 
AF/AT (77,78). Patients with no detectable low voltage 
areas achieved comparable success with PVI alone. This 
personalized approach to ablation stresses the importance 
of durable PVI as well as EAVM in paroxysmal and non-
paroxysmal AF.
Empirical electrical isolation-left atrial appendage  
(EEI-LAA)
Non-PV targets such as SVC, ligament of Marshall, 
coronary sinus, crista terminalis, and left atrial posterior 
wall as a sources for initiating and maintain AF have been 
of interest. Another non-PV target and the most common 
source of thrombus formation in patients with AF-related 
thromboembolism is the LAA (3). In 2010, Di Biase et al. 
revealed that LAA firing was observed in 266/987 (27%) 
patients with AF referred for redo ablation, with LSPAF 
being the most prevalent (58%) (79). EEI-LAA compared 
to standard PVI ablation resulted in a 15% versus 74% 
(P<0.001) recurrence of AF/AT at 12±3 months follow-up, 
respectively. Further stratifying those who had recurrence 
and EEI-LAA, LSPAF was noted to have 68% recurrence, 
compared to 28% in persistent AF and 4% in paroxysmal 
AF which reinforced the difficulty in ablating LSPAF. 
The recent randomized study, BELIEF, investigated the 
effectiveness of additional empirical electrical LAA isolation 
compared to standard PV plus non-PV trigger ablation in 
LSPAF (80). At 12 months follow up, 56% of patients who 
had received EEI-LAA had freedom of atrial arrhythmias 
compared to 28% with standard PV + non-PV ablation. 
Even at 24 months follow up with an average of 1.3 
procedures, freedom from arrhythmia was noted to be 76% 
in those who received EEI-LAA vs. 56% with standard PV 
+ non-PV ablation. Repeat ablation was performed in both 
cohorts: 27/37 (73%) in EEI-LAA group and 35/63 (56%) 
in the standard ablation group. Of note, PV reconnection 
was noted to be similar in both groups (11.1% vs. 11.4%, 
P=1.0). Despite additional mean radiofrequency ablation 
(RFA) time of 16 min, EEI-LAA did not result in a high 
procedural complication rate. Isolation of LAA can be 
performed electrically or potentially with a mechanical 
closure system. In 2015, Lakkireddy et al. studied the impact 
of LAA isolation with the percutaneous endo-epicardial 
LARIAT (SentreHeart, Redwood City, CA) procedure 
prior to standard PVI ablation in patients with persistent 
AF (mean AF duration of 52 months) (81). Freedom from 
atrial arrhythmias at 12 months post-ablation was higher 
in those who received the additional LARIAT procedure 
compared to the standard ablation group (65% vs. 39%; 
P=0.002). The prevalence of LAA as a trigger for AF is still 
quite low and ablation of this specific source may not apply 
to all. A potential issue of LAA-EIA is that the LAA will 
no longer contract if isolation is durable, resulting in stasis 
and lifelong anticoagulation or requirement for closure. 
Another limitation to this approach is the risk of perforation 
if ablation is performed within the LAA.
Hybrid approach
Surgical modalities have been utilized to treat patients 
with symptomatic drug refractory long standing AF. As per 
current guidelines, stand-alone surgical ablation is a Class 
IIb recommendation in highly symptomatic AF patients 
intolerant of other approaches (3). James Cox’s original 
“cut-and-sew” surgical maze procedure (82) which was 
developed to treat this specific population now has evolved 
into the Cox-maze IV surgery (83). The basis of the maze 
procedure is to create lines using RFA, cryoablation, and 
surgical incisions in order to partition atrial tissue to prevent 
the maintenance of re-entrant wavelets. Soon thereafter the 
epicardial-only technique was born, using only RFA alone, 
avoiding cryoablation and surgical incisions. This minimally 
invasive approach would not require cardiopulmonary 
bypass surgery and be able to address the LA using mini-
thoracotomies, thoracoscopy and/or robotics. Similar 
to catheter ablation, the success of the epicardial-only 
approach is greater with paroxysmal versus persistent AF. 
Edgerton et al. demonstrated using a minimally invasive 
surgical approach to perform bilateral PV antral isolation 
and targeted partial autonomic denervation resulted in 
83.7% vs. 56% freedom from AF at 6 months in patients 
with paroxysmal AF and persistent/long-standing persistent 
AF, respectively (84).
In order to improve its efficacy, the hybrid surgical and 
catheter ablation approach was developed. The benefits 
of combining endocardial catheter and epicardial surgical 
ablation include the formation of transmural lesions 
which would be beneficial in the setting of excessive 
scar or increased structural remodeling, and addressing 
the conduction gaps in lesions caused by epicardial 
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ablation. Zembala et al. investigated the safety, feasibility, 
effectiveness of the hybrid approach in 70 patients at with 
persistent and LSPAF (85). Freedom from arrhythmia 
at 6 and 12 months post-procedure was 78.3% and 
84.1%, respectively. Geršak et al. reported similar success 
with convergent procedure for treatment in 76 patients 
with paroxysmal and non-paroxysmal AF and at 4 years 
follow up, 81% of patients were in sinus rhythm (86,87). 
Potential benefits of convergent procedure include less 
radiation exposure, shorter electrophysiology catheter-
based procedure, reduction in the likelihood of esophageal 
injury that may be caused by endocardial ablation. 
However, the procedure is more invasive than purely 
endocardial catheter-based ablation strategies (85). Catheter 
ablation can be performed immediately after the surgical 
thoracoscopic procedure, or months later (Figure 4). A 
benefit of performing both procedures during same setting 
is no requirement for a second administration of anesthesia 
or separate hospitalization. However, allowing enough 
time after surgical ablation would allow reconnections 
or conduction gap to become more apparent and thus 
potentially more successfully ablated. Bisleri et al. utilized 
the sequential staged hybrid approach in 45 patients with 
LSPAF with catheter ablation occurring at least 1 month 
post-surgical ablation. Freedom from AF was noted in 
88.9% (40/45) of patients at 28 months follow up (88). 
Conclusions
Ablation of LSPAF is a challenging task; the success of 
single procedure or different combination of therapies 
is variable and not necessarily reproducible. Is better? 
Combining multiple strategies and/or the necessity for 
multiple ablation procedures result in potentially longer 
fluoroscopy times, increased risk of complications, and 
increased risk for creation of substrate for future atrial 
arrhythmias. Review of multiple trials and observation 
studies have led to the conclusion that durable PVI is 
important irrespective of AF classification. The reason why 
some patients required redo ablation procedures is often due 
to PV reconnection and development of non-PV triggers. A 
tailor-made approach utilized for each patient based on type 
of AF and presence/location of substrate may offer the best 
approach for LSPAF. The role of deMRI to assess for atrial 
fibrosis prior to performing catheter ablation continues to 
evolve and may allow for more effective prognostication 
and pre-procedure planning. Empiric lesion sets appear 
to be ineffective and possibly proarrhythmic. As substrate 
identification becomes more accurately defined, substrate 
modification will likely supplant these empiric approaches. 
Additionally, the collaboration between electrophysiologists 
and surgeons may offer further evolution of techniques 
and technologies to help tear the very difficult LSPAF 
population. The safety and efficacy of the above techniques 
still needs to be evaluated with prospective randomized 
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